TY - JOUR
T1 - Executive summary of clinical practice guide on fracture risk in lifestyle diseases
AU - from the Japan Osteoporosis Society Lifestyle diseases-related Fracture Risk Investigation Committee
AU - Kanazawa, Ippei
AU - Inaba, Masaaki
AU - Inoue, Daisuke
AU - Uenishi, Kazuhiro
AU - Saito, Mitsuru
AU - Shiraki, Masataka
AU - Suzuki, Atsushi
AU - Takeuchi, Yasuhiro
AU - Hagino, Hiroshi
AU - Fujiwara, Saeko
AU - Sugimoto, Toshitsugu
N1 - Publisher Copyright:
© 2020, The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Accumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture. Fractures deteriorate quality of life, activities of daily living, and mortality as well as a lifestyle disease. Therefore, preventing fracture is an important issue for those patients. Although the mechanism of the lifestyle diseases-induced bone fragility is still unclear, not only bone mineral density (BMD) reduction but also bone quality deterioration are involved in it. Because fracture predictive ability of BMD and FRAX® is limited, especially for patients with lifestyle diseases, the optimal management strategy should be established. Thus, when the intervention of the lifestyle diseases-induced bone fragility is initiated, the deterioration of bone quality should be taken into account. We here review the association between lifestyle diseases and fracture risk and proposed an algorism of starting anti-osteoporosis drugs for patients with lifestyle diseases.
AB - Accumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture. Fractures deteriorate quality of life, activities of daily living, and mortality as well as a lifestyle disease. Therefore, preventing fracture is an important issue for those patients. Although the mechanism of the lifestyle diseases-induced bone fragility is still unclear, not only bone mineral density (BMD) reduction but also bone quality deterioration are involved in it. Because fracture predictive ability of BMD and FRAX® is limited, especially for patients with lifestyle diseases, the optimal management strategy should be established. Thus, when the intervention of the lifestyle diseases-induced bone fragility is initiated, the deterioration of bone quality should be taken into account. We here review the association between lifestyle diseases and fracture risk and proposed an algorism of starting anti-osteoporosis drugs for patients with lifestyle diseases.
UR - http://www.scopus.com/inward/record.url?scp=85095567894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095567894&partnerID=8YFLogxK
U2 - 10.1007/s00774-020-01149-3
DO - 10.1007/s00774-020-01149-3
M3 - Article
C2 - 32892240
AN - SCOPUS:85095567894
SN - 0914-8779
VL - 38
SP - 746
EP - 758
JO - Journal of Bone and Mineral Metabolism
JF - Journal of Bone and Mineral Metabolism
IS - 6
ER -
